Review of some hot issues in the disease⁃syndrome combined differentiation， diagnosis and treatment of liver cirrhosis

JIANG Shili; ZHANG Xiao; MU Yongping; LIU Ping

doi:10.16305/j.1007-1334.2023.2306019

您当前的位置：

首页 >

文章列表页 >

Review of some hot issues in the disease⁃syndrome combined differentiation， diagnosis and treatment of liver cirrhosis

更新时间：2023-08-05

- Review of some hot issues in the disease⁃syndrome combined differentiation， diagnosis and treatment of liver cirrhosis
- Shanghai Journal of Traditional Chinese Medicine Vol. 57, Issue 8, Pages: 1-4(2023)
- 作者机构：
  
  1.上海中医药大学附属曙光医院肝病研究所，肝肾疾病病证教育部重点实验室，上海市中医临床重点实验室（上海 201203）
  2.上海中医药大学附属龙华医院（上海 200032）
  3.上海中医药大学交叉科学研究院（上海 201203）
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2023.2306019
  CLC：
扫描看全文
蒋式骊,张笑,慕永平,等.肝硬化的病证结合诊疗若干热点问题述评[J].上海中医药杂志,2023,57(8):1-4.

JIANG Shili,ZHANG Xiao,MU Yongping,et al.Review of some hot issues in the disease⁃syndrome combined differentiation， diagnosis and treatment of liver cirrhosis[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(8):1-4.
蒋式骊,张笑,慕永平,等.肝硬化的病证结合诊疗若干热点问题述评[J].上海中医药杂志,2023,57(8):1-4. DOI： 10.16305/j.1007-1334.2023.2306019.

JIANG Shili,ZHANG Xiao,MU Yongping,et al.Review of some hot issues in the disease⁃syndrome combined differentiation， diagnosis and treatment of liver cirrhosis[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(8):1-4. DOI： 10.16305/j.1007-1334.2023.2306019.

摘要

肝硬化属于中医“肝积”范畴，由本病病变发展所致的病死率较高，病证结合是我国当今中医临床诊疗的主要策略。抗病毒药物及微创技术的快速发展与中医药抗肝纤维化中成药的广泛应用在降低我国肝硬化的发病率和病死率方面彰显出明显特色与优势。主要阐述病证结合策略在肝硬化及其并发症诊治中应用的若干临床议题，包括扶正化瘀法抗肝纤维化/肝硬化，胃镜结合补虚化瘀清热法治疗肝硬化所致上消化道出血，中医辨证诊疗肝硬化所致难治性腹水，滋肾养肝法促进肝细胞恢复代偿等。已有临床疗效的论据揭示了肝硬化的核心病机“气虚血瘀”以及“阴虚瘀热”病机的演变规律，但还需要更多临床研究数据的支撑。认为推进建立病证结合治疗肝硬化及其并发症的临床方案，需要积累更规范的循证依据。

Abstract

Liver cirrhosis belongs to the category of “liver accumulation” in traditional Chinese medicine （TCM）， which has a high mortality rate with its progression. Disease-syndrome combined differentiation is the main TCM clinical treatment strategy in China today. The rapid development of antiviral drugs and minimally invasive technology， as well as the wide application of novel traditional Chinese patent medicines and TCM simple preparations against liver fibrosis， have demonstrated distinctive medical advantages in reducing the morbidity and mortality of cirrhosis in China. This paper mainly expounds several clinical issues in the application of disease-syndrome combined differentiation strategy in the diagnosis and treatment of liver cirrhosis and its complications， including： anti-liver fibrosis/cirrhosis by the method of strengthening vital qi and removing stasis； treatment of upper gastrointestinal bleeding due to cirrhosis by gastroscopy combined with the method of invigorating deficiency， removing stasis and clearing heat； TCM syndrome differentiation， diagnosis and treatment of refractory ascites due to liver cirrhosis； and the method of nourishing the kidney and liver to promote hepatocyte recovery and compensation. The evidence of clinical efficacy has revealed the evolution of the core pathogenesis of liver cirrhosis， namely “qi deficiency and blood stasis” and “yin deficiency and stasis-heat”， but more clinical research data are needed to support the finding. It requires more standardized evidence-based support to advance the establishment of clinical protocols for the disease-syndrome combined differentiation and treatment of cirrhosis and its complications.

关键词

肝硬化病证结合气虚血瘀阴虚瘀热临床研究

Keywords

cirrhosisdisease-syndrome combined differentiationqi deficiency and blood stasisyin deficiency and stasis-heatclinical research

references

王宇，李爽，刘成海.基于《金匮要略》“血痹虚劳篇”探讨肝硬化“扶正化瘀”的中医论治思路［J］. 上海中医药杂志，2023， 57（5）： 1-3.

秦伯未. 谦斋医学讲稿［M］. 上海：上海科学技术出版社，1978： 99-100.

KONG Y Y， LV T T， LI M， et al. Systematic review and meta-analysis： impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver disease［J］. Hepatol Int， 2022， 16（5）： 1052-1063.

蒋式骊，刘平. 肝硬化中西医结合治疗的研究进展［J］．临床肝胆病杂志，2022， 38（9）： 1953-1955.

戈雪婧，赵长青，徐列明. 扶正化瘀胶囊对肝硬化患者生存率的影响［J］. 中华肝脏病杂志，2017， 25（11）： 834-840.

中华医学会消化病学分会微创介入协作组. 经颈静脉肝内门体静脉分流术治疗门静脉高压专家共识［J］. 中华肝脏病杂志，2022， 30（12）： 1349-1364.

SHARMA M， SINGH S， DESAI V， et al. Comparison of therapies for primary prevention of esophageal variceal bleeding： a systematic review and network meta-analysis［J］. Hepatology， 2019， 69（4）： 1657-1675.

DE FRANCHIS R， BOSCH J， GARCIA-TSAO G， et al. Baveno Ⅶ-Renewing consensus in portal hypertension［J］. J Hepatol， 2022， 76（4）： 959-974.

刘成海，幸鹭，赵志敏. 基于病证结合的肝硬化诊治理论探讨与临床实践［J］. 世界中医药，2020， 15（19）： 2831-2834， 2842.

肖定洪，顾杰，蔡虹，等. 扶正化瘀胶囊预防肝硬化患者食管静脉曲张破裂出血的随机对照多中心临床研究［J］. 中华肝脏病杂志，2014， 22（8）： 594-599.

陈冲，吕莹，陈茜蕾，等. 内镜结扎联合中医辨证论治对肝硬化食管静脉曲张破裂出血的二级预防效果［J］. 临床肝胆病杂志，2022， 38（5）： 1075-1080.

DING H G. Road map of the diagnosis and treatment of intractable ascites based on guidelines for the diagnosis and treatment of cirrhotic ascites and related complications［J］. J Clin Hepatol， 2018， 34（1）：31-34.

BIGGINS S W， ANGELI P， GARCIA-TSAO G， et al. Diagnosis， evaluation， and management of ascites， spontaneous bacterial peritonitis and hepatorenal syndrome： 2021 practice guidance by the American Association for the Study of Liver Diseases［J］. Hepatology， 2021， 74（2）： 1014-1048.

CARACENI P， RIGGIO O， ANGELI P， et al. Long-term albumin administration in decompensated cirrhosis（ANSWER）： an open-label randomised trial［J］. Lancet， 2018， 391（10138）： 2417-2429.

DI PASCOLI M， FASOLATO S， PIANO S， et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites［J］. Liver Int， 2019， 39（1）： 98-105.

中华中医药学会脾胃病分会. 肝硬化腹水中医诊疗专家共识意见（2017）［J］．临床肝胆病杂志，2017， 33（9）： 1621-1626.

梁悦，胡永红，刘伟，等. 骨髓间充质干细胞及其外泌体治疗终末期肝病的研究进展［J］. 临床肝胆病杂志，2022， 38（11）： 2643-2648.

谭春雨，刘平. 肝硬化“虚损生积”病机理论溯源及其临床意义［J］. 上海中医药大学学报，2010， 24（4）： 25-28.

周扬，胡鑫才，张华，等. 493例慢性肝炎及肝硬化患者中医证候研究［J］. 中华中医药杂志，2014， 29（12）： 3798-3801.

周扬，胡鑫才，张华，等. 86例肝硬化随访患者中医证候演变研究［J］. 世界中医药，2014， 9（5）： 545-548.

CHEN L， ZHAO C Q， YAO W L， et al. Efficacy and safety of Yanggan Jian in hepatitis B virus-related decompensated cirrhosis： A randomized， double blind， controlled trial［J］. J Clin Transl Hepatol， 2023， 11（1）： 136-143.

Views

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Advances in the diagnosis and treatment of cirrhotic portal hypertension with integrated traditional Chinese and Western medicine

Current status and review of integrated traditional Chinese and Western medicine diagnosis and treatment of cirrhosis complicated with hepatic carcinoma

Gantangyi Recipe improving abnormal glucose metabolism of hepatocyte peroxidative damage in vitro

National TCM master Liu Jiaxiang’s discourse on clinical research and medical ethics in traditional Chinese medicine

Thoughts on practice and management of clinical research of traditional Chinese medicine during normalization stage of prevention and control of COVID⁃19

Related Author

No data

Related Institution

Shanghai Clinical Key Laboratory of Traditional Chinese Medicine

Key Laboratory of Liver and Kidney Diseases， Ministry of Education

Institute of Liver Diseases， Shanghai Academy of Traditional Chinese Medicine

Cell Biology Laboratory，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Institute of Liver Diseases， Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

⁰